• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial.

作者信息

Restelli Umberto, Fabbiani Massimiliano, Di Giambenedetto Simona, Nappi Carmela, Croce Davide

机构信息

Center for Health Economics, Social and Health Care Management, LIUC - Università Cattaneo, Castellanza, Italy.

School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

出版信息

Clinicoecon Outcomes Res. 2017 Sep 27;9:569-571. doi: 10.2147/CEOR.S143377. eCollection 2017.

DOI:10.2147/CEOR.S143377
PMID:29026324
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5627749/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd2/5627749/23d77eb100c3/ceor-9-569Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd2/5627749/23d77eb100c3/ceor-9-569Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd2/5627749/23d77eb100c3/ceor-9-569Fig1.jpg

相似文献

1
Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial.
Clinicoecon Outcomes Res. 2017 Sep 27;9:569-571. doi: 10.2147/CEOR.S143377. eCollection 2017.
2
Erratum: Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum].勘误：基于阿特拉斯-M试验数据，对意大利接受以阿扎那韦为基础的三联疗法的HIV阳性患者简化为阿扎那韦+利托那韦+拉米夫定双重疗法的预算影响分析[勘误]
Clinicoecon Outcomes Res. 2017 Apr 19;9:231. doi: 10.2147/CEOR.S138166. eCollection 2017.
3
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial.根据阿扎那韦-M试验的数据，对意大利接受以阿扎那韦为基础的三联疗法的HIV阳性患者简化为阿扎那韦+利托那韦+拉米夫定双重疗法的预算影响分析。
Clinicoecon Outcomes Res. 2017 Mar 1;9:173-179. doi: 10.2147/CEOR.S127097. eCollection 2017.
4
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).在使用两种核苷（酸）逆转录酶抑制剂（NRTIs）+阿扎那韦/利托那韦（ATV/r）治疗病毒学抑制的 HIV 感染患者中，简化治疗方案为阿扎那韦/利托那韦+拉米夫定的安全性和可行性（简化治疗的阿扎那韦和拉米夫定，AtLaS 初步研究）。
J Antimicrob Chemother. 2013 Jun;68(6):1364-72. doi: 10.1093/jac/dkt007. Epub 2013 Jan 30.
5
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.简化方案为阿扎那韦/利托那韦联合拉米夫定后病毒学抑制的 HIV-1 感染患者的全身炎症标志物：ATLAS-M 亚研究。
J Antimicrob Chemother. 2018 Jul 1;73(7):1949-1954. doi: 10.1093/jac/dky125.
6
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.在 AtLaS-M 随机试验中，与继续三联治疗相比，换用阿扎那韦/利托那韦+拉米夫定双治疗 48 周后血液中 HIV-1 DNA 水平的演变。
J Antimicrob Chemother. 2017 Jul 1;72(7):2055-2059. doi: 10.1093/jac/dkx068.
7
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).在病毒学抑制的HIV-1感染患者中，将治疗简化为阿扎那韦/利托那韦+拉米夫定与维持阿扎那韦/利托那韦+两种核苷类逆转录酶抑制剂的比较：一项随机试验（ATLAS-M）的48周结果
J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557.
8
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.在 HIV-1 病毒学稳定的患者中，使用阿扎那韦-利托那韦联合拉米夫定进行双重治疗与使用阿扎那韦-利托那韦联合两种核苷（酸）逆转录酶抑制剂进行三重治疗的疗效比较（SALT）：一项随机、开放标签、非劣效性试验的 48 周结果。
Lancet Infect Dis. 2015 Jul;15(7):775-84. doi: 10.1016/S1473-3099(15)00097-3. Epub 2015 Jun 7.
9
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.阿扎那韦/利托那韦联合拉米夫定作为维持治疗对病毒学抑制的 HIV 感染患者：一项随机试验的 96 周结果。
J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123.
10
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.在病毒学抑制的HIV感染患者中简化治疗为阿扎那韦/利托那韦+拉米夫定的疗效和安全性：AtLaS试点研究的144周随访
J Antimicrob Chemother. 2015;70(6):1843-9. doi: 10.1093/jac/dkv037. Epub 2015 Feb 26.

引用本文的文献

1
Two-drug regimens for HIV treatment.用于艾滋病治疗的两药方案。
Lancet HIV. 2022 Dec;9(12):e868-e883. doi: 10.1016/S2352-3018(22)00249-1. Epub 2022 Oct 26.

本文引用的文献

1
Erratum: Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum].勘误：基于阿特拉斯-M试验数据，对意大利接受以阿扎那韦为基础的三联疗法的HIV阳性患者简化为阿扎那韦+利托那韦+拉米夫定双重疗法的预算影响分析[勘误]
Clinicoecon Outcomes Res. 2017 Apr 19;9:231. doi: 10.2147/CEOR.S138166. eCollection 2017.
2
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial.根据阿扎那韦-M试验的数据，对意大利接受以阿扎那韦为基础的三联疗法的HIV阳性患者简化为阿扎那韦+利托那韦+拉米夫定双重疗法的预算影响分析。
Clinicoecon Outcomes Res. 2017 Mar 1;9:173-179. doi: 10.2147/CEOR.S127097. eCollection 2017.